186 related articles for article (PubMed ID: 7602345)
1. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
Birrell SN; Roder DM; Horsfall DJ; Bentel JM; Tilley WD
J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
[TBL] [Abstract][Full Text] [Related]
3. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
4. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
6. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment.
Søreide JA; Lea OA; Varhaug JE; Skarstein A; Kvinnsland S
Eur J Surg Oncol; 1992 Apr; 18(2):112-8. PubMed ID: 1582503
[TBL] [Abstract][Full Text] [Related]
8. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
9. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
Lundgren S; Søreide JA; Lea OA
Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
[TBL] [Abstract][Full Text] [Related]
12. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
14. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Buchanan G; Birrell SN; Peters AA; Bianco-Miotto T; Ramsay K; Cops EJ; Yang M; Harris JM; Simila HA; Moore NL; Bentel JM; Ricciardelli C; Horsfall DJ; Butler LM; Tilley WD
Cancer Res; 2005 Sep; 65(18):8487-96. PubMed ID: 16166329
[TBL] [Abstract][Full Text] [Related]
15. St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
[TBL] [Abstract][Full Text] [Related]
16. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
[TBL] [Abstract][Full Text] [Related]
17. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract][Full Text] [Related]
20. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]